Bluejay Diagnostics, Inc. announced that the FDA has agreed to consider Bluejay's plan to pursue a De Novo submission for the Symphony IL-6 Test. In written feedback to the January 2022 submission of the FDA pre-submission briefing package, the FDA stated that Bluejay's Symphony IL-6 Test could be considered for the De Novo pathway.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.51 USD | +11.62% | +17.78% | -58.20% |
31/05 | Bluejay Diagnostics, Inc. announced a financing transaction | CI |
15/05 | Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-58.20% | 1.48M | |
+11.68% | 3.7B | |
+0.37% | 2.28B | |
-21.21% | 1.99B | |
-23.77% | 1.6B | |
+14.81% | 999M | |
+18.25% | 739M | |
-10.04% | 685M | |
-36.12% | 461M | |
-4.47% | 279M |
- Stock Market
- Equities
- BJDX Stock
- News Bluejay Diagnostics, Inc.
- Bluejay Reports FDA Agrees to Consider Its Plan to Pursue A De Novo Regulatory Pathway for the Symphony II-6 Test